Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276) subsidiary Shandong Shengdi obtained China's regulatory approval to conduct Phase II/III clinical trials for HRS-1780 tablets.
The tablets are used for uncontrolled or resistant hypertension, according to a Monday filing with the Shanghai bourse.